Royalty Pharma

Royalty Pharma company information, Employees & Contact Information

Explore related pages

Related company profiles:

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Astellas’ and Pfizer’s Xtandi, Biogen’s Tysabri, Johnson & Johnson’s Tremfya, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.

Company Details

Employees
106
Founded
-
Address
110 East 59th Street,
Phone
212-883-0200
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
New York, New York
Looking for a particular Royalty Pharma employee's phone or email?

Royalty Pharma Questions

News

Royalty Pharma plc Announces Fourth Quarter 2025 Dividend of $0.22 per Class A Ordinary Share - Quiver Quantitative

Royalty Pharma plc Announces Fourth Quarter 2025 Dividend of $0.22 per Class A Ordinary Share Quiver Quantitative

$0.22 Q4 2025 Dividend: Royalty Pharma Declares Payment Dec 10, Record Date Nov 14, 2025 - Stock Titan

$0.22 Q4 2025 Dividend: Royalty Pharma Declares Payment Dec 10, Record Date Nov 14, 2025 Stock Titan

Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference - Yahoo Finance

Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference Yahoo Finance

Q3 2025 Results Nov 5: Royalty Pharma to Report Results and Host Call/Webcast at 8:00 a.m. ET - Stock Titan

Q3 2025 Results Nov 5: Royalty Pharma to Report Results and Host Call/Webcast at 8:00 a.m. ET Stock Titan

Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation - Yahoo Finance

Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation Yahoo Finance

Royalty Pharma and Deloitte Release Landmark Report on Biopharma Royalty Market Insights and Trends - Quiver Quantitative

Royalty Pharma and Deloitte Release Landmark Report on Biopharma Royalty Market Insights and Trends Quiver Quantitative

Henry Fernandez Steps Down from Royalty Pharma's Board of Directors - Yahoo Finance

Henry Fernandez Steps Down from Royalty Pharma's Board of Directors Yahoo Finance

Leading Biopharma Royalty Investor Royalty Pharma to Join Morgan Stanley Healthcare Conference Sept 9 - Stock Titan

Leading Biopharma Royalty Investor Royalty Pharma to Join Morgan Stanley Healthcare Conference Sept 9 Stock Titan

Royalty Pharma plc Announces Resignation of Lead Independent Director Henry Fernandez - Quiver Quantitative

Royalty Pharma plc Announces Resignation of Lead Independent Director Henry Fernandez Quiver Quantitative

Royalty Pharma Reports Second Quarter 2025 Results - Yahoo Finance

Royalty Pharma Reports Second Quarter 2025 Results Yahoo Finance

Leading Biopharma Royalty Investor Royalty Pharma Featured at Bernstein Healthcare Forum 2025 - Stock Titan

Leading Biopharma Royalty Investor Royalty Pharma Featured at Bernstein Healthcare Forum 2025 Stock Titan

Royalty Pharma Appoints Two New Independent Directors, Boosting Independent Board Representation to Over 90% - Quiver Quantitative

Royalty Pharma Appoints Two New Independent Directors, Boosting Independent Board Representation to Over 90% Quiver Quantitative

Royalty Pharma to Share Strategic Updates at Goldman Sachs Healthcare Conference 2025 - Stock Titan

Royalty Pharma to Share Strategic Updates at Goldman Sachs Healthcare Conference 2025 Stock Titan

Royalty Pharma plc to Announce Q1 2025 Financial Results on May 8, 2025 - Quiver Quantitative

Royalty Pharma plc to Announce Q1 2025 Financial Results on May 8, 2025 Quiver Quantitative

Biotech Leader Ted Love Takes Key Board Role at Royalty Pharma, Bringing BIO Leadership Experience - Stock Titan

Biotech Leader Ted Love Takes Key Board Role at Royalty Pharma, Bringing BIO Leadership Experience Stock Titan

87% of Pharma Leaders Embrace Royalty Funding: Royalty Pharma's Groundbreaking Industry Study Reveals Shift - Stock Titan

87% of Pharma Leaders Embrace Royalty Funding: Royalty Pharma's Groundbreaking Industry Study Reveals Shift Stock Titan

Royalty Pharma secures $950 million royalty stake in Amgen’s Imdelltra - PharmiWeb.com

Royalty Pharma secures $950 million royalty stake in Amgen’s Imdelltra PharmiWeb.com

Royalty Pharma Completes RP Management Acquisition - citybiz

Royalty Pharma Completes RP Management Acquisition citybiz

Royalty Pharma plc Completes Internalization of Management Structure with Overwhelming Shareholder Support - Nasdaq

Royalty Pharma plc Completes Internalization of Management Structure with Overwhelming Shareholder Support Nasdaq

rprx-20231231rpplcpressx.htm - SEC.gov

rprx-20231231rpplcpressx.htm SEC.gov

Royalty Pharma Announces $2 Billion Funding Arrangement with Revolution Medicines for Daraxonrasib Development - Nasdaq

Royalty Pharma Announces $2 Billion Funding Arrangement with Revolution Medicines for Daraxonrasib Development Nasdaq

Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline - Yahoo Finance

Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline Yahoo Finance

$2 Billion Debt Offering: Royalty Pharma Secures Major Financing Across Three Long-Term Tranches - Stock Titan

$2 Billion Debt Offering: Royalty Pharma Secures Major Financing Across Three Long-Term Tranches Stock Titan

Mount Sinai Receives Landmark Gift from Royalty Pharma to Advance Health Equity - Mount Sinai

Mount Sinai Receives Landmark Gift from Royalty Pharma to Advance Health Equity Mount Sinai

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million - GlobeNewswire

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million GlobeNewswire

$2.8B Peak Sales Potential: Royalty Pharma Acquires Rights to Breakthrough Lung Cancer Drug Imdelltra - Stock Titan

$2.8B Peak Sales Potential: Royalty Pharma Acquires Rights to Breakthrough Lung Cancer Drug Imdelltra Stock Titan

Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Million - PR Newswire

Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Million PR Newswire

Royalty Pharma Announces Charitable Alliance with The Leukemia & Lymphoma Society (LLS) To Advance Initiatives that Address Healthcare Disparities in Blood Cancer Care and Treatment - PR Newswire

Royalty Pharma Announces Charitable Alliance with The Leukemia & Lymphoma Society (LLS) To Advance Initiatives that Address Healthcare Disparities in Blood Cancer Care and Treatment PR Newswire

Earnings call transcript: Royalty Pharma Q2 2025 shows robust growth - Investing.com

Earnings call transcript: Royalty Pharma Q2 2025 shows robust growth Investing.com

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement - GlobeNewswire

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement GlobeNewswire

Earnings call transcript: Royalty Pharma Q1 2025 misses EPS estimates - Investing.com

Earnings call transcript: Royalty Pharma Q1 2025 misses EPS estimates Investing.com

Royalty Pharma plc (RPRX) and Ferring Pharmaceuticals Enter $500M Royalty Agreement for New Intravesical Gene Therapy Adstiladrin - StreetInsider

Royalty Pharma plc (RPRX) and Ferring Pharmaceuticals Enter $500M Royalty Agreement for New Intravesical Gene Therapy Adstiladrin StreetInsider

Arteaus Therapeutics Sells Emgality Royalty to Royalty Pharma for $260 Million - PR Newswire

Arteaus Therapeutics Sells Emgality Royalty to Royalty Pharma for $260 Million PR Newswire

Disparities in Access to Opioid Use Disorder Medications Persist - MedPage Today

Disparities in Access to Opioid Use Disorder Medications Persist MedPage Today

Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors - The Manila Times

Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors The Manila Times

Biohaven And Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totaling $150 Million - PR Newswire

Biohaven And Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totaling $150 Million PR Newswire

BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets - GlobeNewswire

BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets GlobeNewswire

BioPharma Credit PLC US$ 762 million IPO and admission to trading on the London Stock Exchange, bringing total capital raised by Pharmakon funds to US$ 2.4 billion - PR Newswire

BioPharma Credit PLC US$ 762 million IPO and admission to trading on the London Stock Exchange, bringing total capital raised by Pharmakon funds to US$ 2.4 billion PR Newswire

RPRX Stock Price and Chart — NASDAQ:RPRX - TradingView

RPRX Stock Price and Chart — NASDAQ:RPRX TradingView

Top Royalty Pharma Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant